LeonaBio, Inc. (LONA) intrinsic value & 10-year financials
LeonaBio, Inc. (LONA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $5.20
- Market cap
- $22.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -33.3%
- Free cash flow (FY2025)
- —
LONA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$105.6M | -$24.70 | — | — | 465.5% |
| FY2024 | — | -$96.9M | -$2.52 | -$97.2M | — | -509.8% |
| FY2023 | — | -$117.7M | -$3.09 | -$101.1M | — | -129.6% |
| FY2022 | — | -$95.6M | -$2.53 | -$73.6M | — | -54.2% |
| FY2021 | — | -$54.9M | -$1.49 | -$44.7M | — | -25.7% |
| FY2020 | — | -$20.0M | — | -$26.4M | — | -9.3% |
| FY2019 | — | -$5.2M | — | — | — | 29.8% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
LeonaBio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
LeonaBio, Inc. has historically struggled to out-earn its cost of capital, averaging just -27.1% ROIC.
LeonaBio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
LeonaBio, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.